A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)
Phase 3 – large-scale trial before approval
Conditions:
Advanced Hepatocellular Carcinoma
Sponsor: AstraZeneca AB
trial.available_in:
БГ
Overview
Trial status: Authorised
PFS, ORR, DoR by BICR per RECIST v1.1
Overall Survival (OS)
Description
PFS, ORR, DoR by BICR per RECIST v1.1
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 273 participants
Interventions
IMJUDO 20 mg/ml concentrate for solution for infusion.
Drug
IMJUDO 20 mg/ml concentrate for solution for infusion.
БГ